GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
In both groups, the clinical improvement exceeded the conventional definition of clinical meaningfulness, in which a 15-letter gain is considered meaningful.
- In both groups, the clinical improvement exceeded the conventional definition of clinical meaningfulness, in which a 15-letter gain is considered meaningful.
- The safety profile of the gene therapy continues to be favorable and comparable between bilaterally treated patients and unilaterally treated patients.
- “Witnessing results like these energizes the GenSight team’s drive to restore early access availability for eligible patients by Q3 this year,” said Laurence Rodriguez, Chief Executive Officer of GenSight.
- The Company aims to resume early access in France under the Autorisation de l’accès compassionnel (AAC) program in Q3 2024.